Reviewing Fractyl Health (GUTS) and Its Peers

Fractyl Health (NASDAQ:GUTS) is one of 237 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Fractyl Health to related businesses based on the strength of its valuation, earnings, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Fractyl Health and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fractyl Health	-64,849.48%	N/A	-57.21%
Fractyl Health Competitors	-570.81%	-156.88%	-27.81%

Earnings & Valuation

This table compares Fractyl Health and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fractyl Health	$120,000.00	-$77.09 million	-0.17
Fractyl Health Competitors	$1.01 billion	$10.43 million	-6.57

Fractyl Health’s competitors have higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

47.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.3% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Fractyl Health and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	0	0	3	0	3.00
Fractyl Health Competitors	1908	4906	9173	268	2.48

Fractyl Health presently has a consensus price target of $22.00, suggesting a potential upside of 952.63%. As a group, “Surgical & medical instruments” companies have a potential upside of 17.08%. Given Fractyl Health’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Fractyl Health is more favorable than its competitors.

Summary

Fractyl Health competitors beat Fractyl Health on 7 of the 12 factors compared.

About Fractyl Health

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.